查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472282

抗體生產市場：按產品、製程和最終用戶分類：2023-2032 年全球機會分析和產業預測

Antibody Production Market By Product, By Process, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 276 Pages | 商品交期: 2-3個工作天內

價格

2022年抗體生產市場價值為123億美元，預計到2032年將達到294億美元，2023年至2032年的複合年成長率為9.1%。抗體產生是指免疫系統的特殊細胞（稱為 B 細胞）產生抗體以應對細菌、病毒和其他病原體等外來物質的存在的過程。抗體，也稱為免疫球蛋白，是一種 Y 形蛋白質，特異性識別並結合抗原（病原體表面存在的特異性分子）。

抗體生產市場-IMG1

當 B 細胞遇到與其特異性受體相符的抗原時，抗體產生過程就開始了。這種遭遇會觸發 B 細胞活化和增殖，從而產生大量相同的 B 細胞（稱為克隆）。活化的 B 細胞隨後分化為漿細胞，漿細胞是抗體生產工廠。漿細胞將大量抗體分泌到血液和其他體液中，在那裡它們與病原體結合併中和病原體，或標記它們以被其他免疫細胞破壞。

推動抗體製造市場成長的因素包括需要標靶治療的慢性疾病數量的增加、生物技術的進步提高了生產效率和可擴展性、對用於治療和研究應用的單株抗體的需求不斷增加以及基於抗體的研究和發展政府有支持措施來促進這一點。此外，由於研發投資的增加以及生技藥品治療方法的採用增加，生物製藥行業正在經歷快速成長。抗體佔生物製藥的大部分，正在推動對抗體製造技術和服務的需求。

此外，旨在促進生物技術研究和開發的政府舉措以及對生物製藥公司和學術機構的財政支持正在推動抗體生產市場的創新和成長。官民合作關係和津貼計畫也有助於擴大抗體相關研究和商業化。例如，美國國立衛生研究院 (NIH) 計劃在 2023 年推出抗體生產計劃，美國研究建立和維持免疫反應的機制，包括廣泛中和 HIV 抗體以預防 HIV 感染。因此，政府加大抗體研究和商業化舉措將進一步推動市場成長。此外，單株抗體（mAb）由於其高特異性和有效性而在各個治療領域中獲得了廣泛接受。核准的單株抗體醫藥品數量的增加以及在腫瘤學、免疫學和其他領域的應用不斷擴大正在推動對抗體生產和試劑的需求。

然而，與抗體開發和生產相關的高成本是抗體生產市場成長的主要限制。抗體開發需要一系列複雜且資源集中的步驟，包括抗原選擇、融合瘤和噬菌體展示庫生成、抗體篩檢和最佳化。這些過程需要專業知識、精密設備和廣泛的實驗室資源，增加了開發成本。此外，治療性抗體的生產涉及大量的細胞培養、精製、配製和品管步驟，所有這些都會導致更高的生產成本並可能抑制市場成長。另一方面，生物製藥行業的成長和研發投資的增加為市場成長帶來了機會。

抗體生產市場按產品、製程、最終用戶和地區細分。依產品分類，市場分為設備和消耗品。設備部分進一步分為反應器、層析法系統和過濾系統。依流程分類，市場分為上游工程和下游流程。依最終用戶分類，可分為製藥/生技公司、CRO/CDMO 等。

相關人員的主要利益

  • 本報告定量分析了2022年至2032年抗體生產市場分析的細分市場、當前趨勢、估計/趨勢和動態，以識別一般抗體生產市場的機會。
  • 它提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 對抗體生產市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與企業定位有助於基準化分析，並提供對市場參與企業當前地位的清晰了解。
  • 該報告包括對區域和全球抗體生產市場趨勢、主要企業、細分市場、應用細分和市場成長策略的分析。

該報告可以客製化（可能會產生額外的費用和時間，因此請聯絡您的銷售負責人以了解詳細資訊）。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章 抗體生產市場：依產品

  • 概述
  • 裝置
    • 設備市場：依產品分類
  • 消耗品

第5章抗體製造市場：依製程分類

  • 概述
  • 上游工程
  • 下游工藝

第6章 抗體製造市場：依最終用戶分類

  • 概述
  • 製藥和生物技術公司
  • CRO 和 CDMO
  • 其他

第7章 抗體製造市場 抗體製造市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • Gcc
    • 南非
    • 北非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Cellabcdmo
  • Agilent Technologies, Inc.
  • Genetix Biotech Asia Pvt. Ltd.
  • Cell Culture Company
  • Bio-Rad Laboratories, Inc.
  • TECNIC
  • Merck KGaA
  • Danaher Corporation
Product Code: A03233

The antibody production market was valued at $12.3 billion in 2022 and is projected to reach $29.4 billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.

Antibody Production Market - IMG1

The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.

Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.

Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth. Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.

However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.

The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End User

  • Pharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

By Product

  • Instruments
    • Type
    • Bioreactors
    • Chromatography Systems
    • Filtration Systems
  • Consumables

By Process

  • Upstream Processing
  • Downstream Processing

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Thermo Fisher Scientific Inc.
    • Sartorius AG
    • Cellabcdmo
    • Agilent Technologies, Inc.
    • Genetix Biotech Asia Pvt. Ltd.
    • Cell Culture Company
    • Bio-Rad Laboratories, Inc.
    • TECNIC
    • Merck KGaA
    • Danaher Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Instruments Antibody Production Market by Type
  • 4.3. Consumables
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Upstream Processing
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Downstream Processing
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. CROs and CDMOs
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Process
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product
      • 7.2.5.1.2. Market size and forecast, by Process
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product
      • 7.2.5.2.2. Market size and forecast, by Process
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product
      • 7.2.5.3.2. Market size and forecast, by Process
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Process
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product
      • 7.3.5.1.2. Market size and forecast, by Process
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product
      • 7.3.5.2.2. Market size and forecast, by Process
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product
      • 7.3.5.3.2. Market size and forecast, by Process
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product
      • 7.3.5.4.2. Market size and forecast, by Process
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product
      • 7.3.5.5.2. Market size and forecast, by Process
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product
      • 7.3.5.6.2. Market size and forecast, by Process
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Process
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product
      • 7.4.5.1.2. Market size and forecast, by Process
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product
      • 7.4.5.2.2. Market size and forecast, by Process
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product
      • 7.4.5.3.2. Market size and forecast, by Process
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product
      • 7.4.5.4.2. Market size and forecast, by Process
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product
      • 7.4.5.5.2. Market size and forecast, by Process
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product
      • 7.4.5.6.2. Market size and forecast, by Process
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Process
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product
      • 7.5.5.1.2. Market size and forecast, by Process
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Product
      • 7.5.5.2.2. Market size and forecast, by Process
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Product
      • 7.5.5.3.2. Market size and forecast, by Process
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Product
      • 7.5.5.4.2. Market size and forecast, by Process
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Product
    • 7.6.3. Market size and forecast, by Process
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Product
      • 7.6.5.1.2. Market size and forecast, by Process
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Product
      • 7.6.5.2.2. Market size and forecast, by Process
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Product
      • 7.6.5.3.2. Market size and forecast, by Process
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Product
      • 7.6.5.4.2. Market size and forecast, by Process
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Thermo Fisher Scientific Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Sartorius AG
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Cellabcdmo
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Agilent Technologies, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Genetix Biotech Asia Pvt. Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Cell Culture Company
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Bio-Rad Laboratories, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. TECNIC
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Merck KGaA
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Danaher Corporation
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL INSTRUMENTS ANTIBODY PRODUCTION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 06. ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 09. ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTIBODY PRODUCTION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTIBODY PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. CANADA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. UK ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. UK ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 38. UK ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. CHINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. INDIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. INDIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 90. GCC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 91. GCC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 92. GCC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 103. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 104. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 105. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
  • TABLE 106. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 107. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 108. SARTORIUS AG: KEY EXECUTIVES
  • TABLE 109. SARTORIUS AG: COMPANY SNAPSHOT
  • TABLE 110. SARTORIUS AG: PRODUCT SEGMENTS
  • TABLE 111. SARTORIUS AG: SERVICE SEGMENTS
  • TABLE 112. SARTORIUS AG: PRODUCT PORTFOLIO
  • TABLE 113. SARTORIUS AG: KEY STRATERGIES
  • TABLE 114. CELLABCDMO: KEY EXECUTIVES
  • TABLE 115. CELLABCDMO: COMPANY SNAPSHOT
  • TABLE 116. CELLABCDMO: PRODUCT SEGMENTS
  • TABLE 117. CELLABCDMO: SERVICE SEGMENTS
  • TABLE 118. CELLABCDMO: PRODUCT PORTFOLIO
  • TABLE 119. CELLABCDMO: KEY STRATERGIES
  • TABLE 120. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 121. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 122. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 123. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
  • TABLE 124. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 125. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
  • TABLE 126. GENETIX BIOTECH ASIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 127. GENETIX BIOTECH ASIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 128. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 129. GENETIX BIOTECH ASIA PVT. LTD.: SERVICE SEGMENTS
  • TABLE 130. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 131. GENETIX BIOTECH ASIA PVT. LTD.: KEY STRATERGIES
  • TABLE 132. CELL CULTURE COMPANY: KEY EXECUTIVES
  • TABLE 133. CELL CULTURE COMPANY: COMPANY SNAPSHOT
  • TABLE 134. CELL CULTURE COMPANY: PRODUCT SEGMENTS
  • TABLE 135. CELL CULTURE COMPANY: SERVICE SEGMENTS
  • TABLE 136. CELL CULTURE COMPANY: PRODUCT PORTFOLIO
  • TABLE 137. CELL CULTURE COMPANY: KEY STRATERGIES
  • TABLE 138. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 139. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 140. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 141. BIO-RAD LABORATORIES, INC. : SERVICE SEGMENTS
  • TABLE 142. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 143. BIO-RAD LABORATORIES, INC. : KEY STRATERGIES
  • TABLE 144. TECNIC: KEY EXECUTIVES
  • TABLE 145. TECNIC: COMPANY SNAPSHOT
  • TABLE 146. TECNIC: PRODUCT SEGMENTS
  • TABLE 147. TECNIC: SERVICE SEGMENTS
  • TABLE 148. TECNIC: PRODUCT PORTFOLIO
  • TABLE 149. TECNIC: KEY STRATERGIES
  • TABLE 150. MERCK KGAA: KEY EXECUTIVES
  • TABLE 151. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 152. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 153. MERCK KGAA: SERVICE SEGMENTS
  • TABLE 154. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 155. MERCK KGAA: KEY STRATERGIES
  • TABLE 156. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 157. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 158. DANAHER CORPORATION: PRODUCT SEGMENTS
  • TABLE 159. DANAHER CORPORATION: SERVICE SEGMENTS
  • TABLE 160. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 161. DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. ANTIBODY PRODUCTION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTIBODY PRODUCTION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN ANTIBODY PRODUCTION MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN ANTIBODY PRODUCTION MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTIBODY PRODUCTION MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. ANTIBODY PRODUCTION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 22. U.S. ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. COLOMBIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. ARGENTINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. GCC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. NORTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF MEA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: ANTIBODY PRODUCTION MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022